Ausgabe 3/2024
Inhalt (17 Artikel)
15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives
- Open Access
- review
Peter Valent, Emir Hadzijusufovic, Irina Sadovnik, Thomas W. Grunt, Barbara Peter, Michael Willmann, Harald Herrmann, Daniel Ivanov, Gregor Eisenwort, Heidrun Karlic, Georg Greiner, Karoline V. Gleixner, Thomas Rülicke, Maik Dahlhoff, Philipp Staber, Wolfgang R. Sperr, Michael Pfeilstöcker, Thomas Lion, Felix Keil, Gregor Hoermann
Advanced stage Hodgkinʼs lymphoma 2024—Update on first line treatment
- short review
Barbara Lehner, Michael Panny
American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia
- short review
Thomas Nösslinger
Liquid profiling for patients with advanced cancer is ready for clinical integration
- Open Access
- short review
Samantha O. Hasenleithner, Ellen Heitzer
The molecular tumor board—a key element of precision oncology
- Open Access
- Diagnostik in der Onkologie
- short review
Laura Boos, Andreas Wicki
Antibody–drug conjugates (ADCs) in lung cancer treatment
- Open Access
- short review
Romana E. Wass, David Lang, Andreas Horner, Bernd Lamprecht
Emerging drugs in breast cancer: a focus on antibody–drug conjugates and novel treatment options in luminal disease
- Open Access
- Short Review
Rupert Bartsch
Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023
- Open Access
- short review
Jan-Paul Bohn
Importance of allogeneic stem cell transplantation in myelofibrosis
- Open Access
- short review
Klaus Hirschbühl, Christoph Schmid
β-adrenergic modulation of IL-6/gp130 and SOCS-1 in multiple myeloma: therapeutic strategy for stress induced-inflammatory response
- original report
Raika Naiebi, Saeid Abroun, Amir Atashi, Leila Shafiee, Mohammadarian Akbari, Mohammad Hasan Maleki, Morvarid Siri
Seminal vesicle metastasis from transverse colon adenocarcinoma: a unique case report
- Open Access
- case report
Juliana Arenas Hoyos, Julian Serrano Giraldo, Andres Felipe Gutierrez Rojas
